The upcoming year 2016 will be marked by two significant events: the ninevalent HPV vaccine will be available in Europe and The Netherlands will be the first country to implement primary HPV screening for the precursors of cervical cancer.
Europe has a substantial burden of HPV-related disease. More than 44,000 new cases of HPV-related anogenital cancers affect men and women in Europe annually . In addition, more than 15,000 new cases of mainly HPV-16-related oropharyngeal cancer affect predominantly males. The estimation of genital precancer is in the order of 300,000 or more annual cases. Genital warts are a substantial limitation in the sexual wellbeing; probably more than 800,000 new cases are diagnosed in European females and males every year .
Click here to view the full article in Future Virology.